BCRX Filings — Biocryst Pharmaceuticals, Inc. - FilingSpy
BCRX
Biocryst Pharmaceuticals, Inc.
A biopharmaceutical company that develops medicines for rare diseases, BioCryst's flagship product is Orladeyo, an oral once-daily pill that prevents attacks of hereditary angioedema, a rare genetic condition causing sudden, painful swelling. Founded in 1986 in Birmingham, Alabama, the name blends "bio" with "cryst," a nod to the X-ray crystallography technique its scientists use to design drugs at the molecular level. The company also markets RAPIVAB, an antiviral treatment for influenza.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -487.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.